You are here: Home » International » News » Others
Business Standard

Oxford University launches Covid-19 vaccine study on children

The University of Oxford has launched the first study to assess the safety and immune responses in children and young adults of its coronavirus vaccine

Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Press Trust of India  |  London 

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Representational image

The University of Oxford has launched the first study to assess the safety and immune responses in children and young adults of its vaccine.

The university said that previous trials of its ChAdOx1 nCoV-19 jabs, which are being produced by AstraZeneca and also have a tie-up with the Serum Institute of India, have shown that it is safe, produces strong immune system responses and has high efficacy in all adults.

From Friday, it would be extending its trials to assess if children and young adults aged 6-17 years also show a good immune response to from it.

While most children are relatively unaffected by and are unlikely to become unwell with the infection, it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination, said Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial.

These new trials will extend our understanding of control of SARS-CoV2 to younger age groups, he said.

This new trial, a single-blind, randomised Phase II trial, will enrol 300 volunteers, with up to 240 of these volunteers receiving the ChAdOx1 nCoV-19 vaccine and the remainder a control meningitis vaccine, which has been shown to be safe in children but is expected to produce similar reactions, such as a sore arm.

The COVID-19 pandemic has had a profound negative impact on the education, social development and emotional well-being of children and adolescents, beyond illness and rare severe disease presentations, said Rinn Song, Paediatrician and Clinician-Scientist, Oxford Vaccine Group.

It is therefore important to collect data on the safety and the immune response to our in these age groups, so that they could potentially benefit from inclusion in vaccination programmes in the near future, he said.

After the launch of the trial funded by the National Institute for Health Research (NIHR) and AstraZeneca this week, the first vaccinations are expected during the course of this month.

This study will play an important role in helping to protect children in the future. We've already seen that the vaccine is safe and effective in adults, and our understanding of how children are affected by the coronavirus continues to evolve, said Grace Li, Paediatric Clinical Research Fellow, Oxford Vaccine Group.

The university said it has teamed up with three partner sites in London, Southampton and Bristol for this extended vaccine trial.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, February 13 2021. 19:21 IST